Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03705065 · ClinicalTrials.gov registry record · Phase 4
Bupivacaine HCl PK and Safety in Augmentation Mammoplasty
A Phase 4 study, sponsored by Heron Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT03705065: Completed Phase 4 study, sponsored by Heron Therapeutics.
NCT03705065 is a Phase 4 study that has completed, run by Heron Therapeutics. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03705065, a Phase 4 study, has completed, sponsored by Heron Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 4, randomized, open-label study of bupivacaine HCl administered either by instillation into the surgical site or by injection into the surgical site in subjects undergoing bilateral submuscular augmentation mammoplasty under general anesthesia.
Interventions
- DRUG Bupivacaine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-09-19 |
| Est. Completion | 2018-11-05 |
| Phase | Phase 4 |
What the finished NCT03705065 record still lists
NCT03705065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Bupivacaine HCl is the first listed.
NCT03705065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03705065 about?
NCT03705065 is a clinical study titled "Bupivacaine HCl PK and Safety in Augmentation Mammoplasty". This is a Phase 4, randomized, open-label study of bupivacaine HCl administered either by instillation into the surgical site or by injection into the surgical site in subjects undergoing bilateral submuscular augmentation mammoplasty under general anesthesia.
What is the current status of trial NCT03705065?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2018-09-19. Estimated completion is 2018-11-05.
What interventions are being tested in trial NCT03705065?
The interventions under investigation include: Bupivacaine HCl (DRUG).
Who is sponsoring clinical trial NCT03705065?
This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03705065's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI